Last $4.26 USD
Change Today +0.16 / 3.90%
Volume 2.9M
As of 3:52 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - amicus therapeutics inc (FOLD)

Name (Connections)Board RelationshipsTitleKey Developments
Glenn Sblendorio 54 RelationshipsDirector and Chairman of Audit Committee 
Michael Raab 31 RelationshipsIndependent Director, Member of Audit Committee and Member of Compensation Committee 
Robert Essner 70 RelationshipsDirector and Member of Audit Committee 

Compensation Committee* - amicus therapeutics inc (FOLD)

Name (Connections)Board RelationshipsTitle
Sol Barer Ph.D. 174 RelationshipsDirector and Member of Compensation Committee
Margaret McGlynn R.Ph 60 RelationshipsDirector, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
Michael Raab 31 RelationshipsIndependent Director, Member of Audit Committee and Member of Compensation Committee
James Topper M.D., Ph.D. 74 RelationshipsIndependent Director, Chairman of Science & Technology Committee and Member of Compensation Committee
FOLD Compensation vs. Industry
561.4K
372.7K
Chief Executive Officer
334.8K
273.5K
Chief Financial Officer
351.4K
353.2K
Chief Operating Officer
Share price activity for AMICUS THERAPEUTICS INC (FOLD)
52 Week Price Performance
FOLD
Industry Average

Nominating Committee* - amicus therapeutics inc (FOLD)

Name (Connections)Board RelationshipsTitleKey Developments
Donald Hayden Jr. 98 RelationshipsLead Independent Director and Chairman of Nominating & Corporate Governance CommitteeAmicus Therapeutics, Inc. Announces Executive Changes
03/3/14
Margaret McGlynn R.Ph 60 RelationshipsDirector, Chairman of Compensation Committee and Member of Nominating & Corporate Governance CommitteeAmicus Therapeutics, Inc. Appoints Bradley L. Campbell as Chief Operating Officer
12/5/13
Michael Barrett Ph.D. 187 RelationshipsDirector, Member of Nominating & Corporate Governance Committee and Member of Science & Technology CommitteeAmicus Therapeutics, Inc. Begins to Implement Restructuring Plan; Plans to Reduce Workforce by 14%; David J. Lockhart Leaves the Company as Chief Science Officer, Effective as of December 31, 2013
11/21/13
Ted Love M.D. 104 RelationshipsDirector, Member of Nominating & Corporate Governance Committee and Member of Science & Technology CommitteePol F. Boudes to Leave Amicus Therapeutics, Inc. as Chief Medical Officer, Effective April 30, 2013
02/22/13

Corporate Governance Committee* - amicus therapeutics inc (FOLD)

Name (Connections)Board RelationshipsTitle
Michael Barrett Ph.D. 187 RelationshipsDirector and Member of Compensation Committee
Donald Hayden Jr. 98 RelationshipsDirector, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
Ted Love M.D. 104 RelationshipsIndependent Director, Member of Audit Committee and Member of Compensation Committee
Margaret McGlynn R.Ph 60 RelationshipsIndependent Director, Chairman of Science & Technology Committee and Member of Compensation Committee
FOLD and Competitor
Insiders vs. External
Board
5%
95%
Amicus Therapeutics, Inc.
Insiders
External Board Members

Advisory Committee* - amicus therapeutics inc (FOLD)

Name (Board Relationships)/Title Board Affiliations
Michel Bouvier 18 Relationships
Member of Scientific Advisory Board
No other board affiliations
Barry Byrne 25 Relationships
Member of Scientific Advisory Board
No other board affiliations
Dominique Germain 18 Relationships
Member of Medical Advisory Board
No other board affiliations
Stuart Kornfeld 18 Relationships
Member of Scientific Advisory Board
No other board affiliations
David Lockhart 18 Relationships
Member of Scientific Advisory Board
No other board affiliations
Pramod Mistry 18 Relationships
Member of Medical Advisory Board
No other board affiliations
Marc Patterson 18 Relationships
Member of Medical Advisory Board
No other board affiliations
Gregory Petsko 120 Relationships
Member of Scientific Advisory Board
No other board affiliations
Thomas Voit 28 Relationships
Member of Medical Advisory Board
No other board affiliations
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $4.26 USD +0.16

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies
 

Industry Analysis

FOLD

Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 322.2x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 217.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.